GSE173483 nutlin-3 U2OS 3 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE173483_nutlin-3_U2OS_3_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE173483_nutlin-3_U2OS_3_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE173483_nutlin-3_U2OS_3_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE173483_nutlin-3_U2OS_3_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

ral guanine nucleotide dissociation stimulator like 2

Gene

H3.3 histone A

Gene

MSL complex subunit 3B

Gene

FGD5 antisense RNA 1

Gene

HOXD antisense growth-associated long non-coding RNA

Gene

long intergenic non-protein coding RNA 3040

Gene

long intergenic non-protein coding RNA 667

Gene

LOXL1 antisense RNA 1

Gene

FSHD region gene 1 family member C, pseudogene

Gene

HOX transcript antisense RNA

  • Gene

    ral guanine nucleotide dissociation stimulator like 2



  • Gene

    MSL complex subunit 3B


  • Gene

    FGD5 antisense RNA 1


  • Gene

    HOXD antisense growth-associated long non-coding RNA


  • Gene

    long intergenic non-protein coding RNA 3040


  • Gene

    long intergenic non-protein coding RNA 667


  • Gene

    LOXL1 antisense RNA 1


  • Gene

    FSHD region gene 1 family member C, pseudogene


  • Gene

    HOX transcript antisense RNA

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.